|4.20||-0.1500||-3.45%||Vol 332.89K||1Y Perf 20.22%|
|Dec 2nd, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||7.80||Analyst Rating||Moderate Buy 2.00|
|Potential %||85.71||Finscreener Ranking||★ 40.40|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||☆ 33.56|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★+ 41.64|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||73.25||Earnings Rating||Strong Buy|
|Market Cap||364.98M||Earnings Date||10th Nov 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.48|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||255.53K|
|Avg. Monthly Volume||356.87K|
|Avg. Quarterly Volume||338.11K|
Wave Life Sciences Ltd. (NASDAQ: WVE) stock closed at 4.2 per share at the end of the most recent trading day (a -3.45% change compared to the prior day closing price) with a volume of 332.89K shares and market capitalization of 364.98M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 301 people. Wave Life Sciences Ltd. CEO is Paul B. Bolno.
The one-year performance of Wave Life Sciences Ltd. stock is 20.22%, while year-to-date (YTD) performance is 33.76%. WVE stock has a five-year performance of -89.33%. Its 52-week range is between 1.16 and 5.31, which gives WVE stock a 52-week price range ratio of 73.25%
Wave Life Sciences Ltd. currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 10.21, a price-to-sale (PS) ratio of 93.04, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -80.05%, a ROC of -337.71% and a ROE of -1 204.78%. The company’s profit margin is -%, its EBITDA margin is -3 475.70%, and its revenue ttm is $4.18 Million , which makes it $0.05 revenue per share.
Of the last four earnings reports from Wave Life Sciences Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Wave Life Sciences Ltd.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Wave Life Sciences Ltd. is Moderate Buy (2), with a target price of $7.8, which is +85.71% compared to the current price. The earnings rating for Wave Life Sciences Ltd. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Wave Life Sciences Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Wave Life Sciences Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.91, ATR14 : 0.45, CCI20 : 40.63, Chaikin Money Flow : -0.22, MACD : 0.01, Money Flow Index : 54.77, ROC : 32.08, RSI : 51.10, STOCH (14,3) : 72.36, STOCH RSI : 0.21, UO : 51.61, Williams %R : -27.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Wave Life Sciences Ltd. in the last 12-months were: Chandra Vargeese (Sold 10 603 shares of value $24 599 ), Christopher Francis (Sold 20 990 shares of value $42 075 ), Kyle Moran (Sold 14 225 shares of value $29 897 ), Michael A. Panzara (Sold 27 317 shares of value $53 241 ), Paul B. Bolno (Sold 66 651 shares of value $134 530 )
Thu, 10 Nov 2022 19:20 GMT Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Ayr Wellness (AYRWF)- TipRanks. All rights reserved.
Fri, 23 Sep 2022 04:35 GMT Wave Life Sciences (WVE) Receives a Hold from SVB Securities- TipRanks. All rights reserved.
Tue, 20 Sep 2022 15:55 GMT Wave Life Sciences (WVE) Receives a Buy from Mizuho Securities- TipRanks. All rights reserved.
Tue, 20 Sep 2022 15:55 GMT Wave Life Sciences (WVE) Gets a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Fri, 12 Aug 2022 09:48 GMT Why Is Wave Life Sciences Stock Surging Despite Q2 Miss- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.